SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.6% Higher – Still a Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price traded up 9.6% during trading on Thursday . The company traded as high as $8.94 and last traded at $8.9750. 3,523,877 shares traded hands during trading, a decline of 57% from the average session volume of 8,140,919 shares. The stock had previously closed at $8.19.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group upped their target price on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Stock Performance

The company has a market capitalization of $1.62 billion, a PE ratio of -35.78 and a beta of 2.50. The business’s 50-day moving average is $5.96 and its 200-day moving average is $4.43.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of SELLAS Life Sciences Group by 2.8% in the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock worth $11,012,000 after acquiring an additional 185,106 shares during the last quarter. Anson Funds Management LP grew its stake in shares of SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after acquiring an additional 5,757,938 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of SELLAS Life Sciences Group by 35.9% in the fourth quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after acquiring an additional 812,953 shares during the last quarter. Marshall Wace LLP grew its stake in shares of SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after acquiring an additional 2,704,007 shares during the last quarter. Finally, State Street Corp grew its stake in shares of SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock worth $8,249,000 after acquiring an additional 827,257 shares during the last quarter. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.